Cybin Inc. announced changes to its scientific management team. Following the achievement of the final milestones as contemplated by the terms of a contribution agreement dated December 4, 2020 between Cybin and Adelia Therapeutics Inc., a wholly controlled subsidiary of Cybin, Michael Palfreyman Ph.D. and Brett Greene, who joined Cybin as part of the acquisition of Adelia, will leave their roles as Chief R&D Officer and Chief Innovations Officer, respectively, and transition into advisory roles at Cybin. Alex Nivorozhkin Ph.D., one of Adelia's founders, will continue in his role as Chief Scientific Officer of Cybin.